The three US patents 8,808,725, 8,790,681 and 8,802,115, and Japanese patent 5536793 allows the use of modified coral scaffolds to treat cartilage and bone defects. It also covers a wide range of claims comprising treatment of cartilage and osteochondral defects, osteoarthritis and different joint disorders.

Agili-C implant, a bi-phasic, coralline-hyaluronate composite scaffold, has undergone chemical, physical and biological modifications, in order to secure the patents, CartiHeal said.

CartiHeal founder and CEO Nir Altschuler said the four patents strengthen firm’s IP portfolio and positions the company at the forefront of innovative technologies in the field of cartilage regeneration.

"Cartilage regeneration represents one of medicine’s most challenging unmet needs. We are proud to say that CartiHeal and its breakthrough technology are able to meet this challenge," Altschuler added.

CartiHeal noted that CE-marked Agili-C has demonstrated the regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents.